Skip to main content
Journal cover image

Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

Publication ,  Journal Article
Levin, ED; Wilson, W; Rose, JE; McEvoy, J
Published in: Neuropsychopharmacology
November 1996

Nearly 90% of schizophrenics smoke cigarettes, considerably higher than the general population's rate of 25%. There is some indication that schizophrenics may smoke as a form of self-medication. Nicotine has a variety of pharmacologic effects that may both counteract some of the cognitive deficits of schizophrenia and counteract some of the adverse side effects of antipsychotic drugs. In the current study, we assessed the interactions of haloperidol and nicotine on cognitive performance of a group of schizophrenics. These patients were in a double-blind study, randomly assigning them to low, moderate, and high dose levels of haloperidol. The subjects, all smokers, came to the laboratory on four different mornings after overnight deprivation from cigarettes. In a double-blind fashion, they were administered placebo, low (7 mg/day), medium (14 mg/day), or high (21 mg/day) dose nicotine skin patches. Three hours after administration of the skin patch, the subjects were given a computerized cognitive test battery including: simple reaction time, complex reaction time (spatial rotation), delayed matching to sample, the Sternberg memory test, and the Conners continuous performance test (CPT). With the placebo nicotine patch, there was a haloperidol dose-related impairment in delayed matching to sample choice accuracy and an increase in response time on the complex reaction time task. Nicotine caused a dose-related reversal of the haloperidol-induced impairments in memory performance and complex reaction time. In the CPT, nicotine reduced the variability in response that is associated with attentional deficit. These results demonstrate the effects of nicotine in reversing some of the adverse side effects of haloperidol and improving cognitive performance in schizophrenia.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuropsychopharmacology

DOI

ISSN

0893-133X

Publication Date

November 1996

Volume

15

Issue

5

Start / End Page

429 / 436

Location

England

Related Subject Headings

  • Schizophrenia
  • Reaction Time
  • Psychiatry
  • Nicotinic Agonists
  • Nicotine
  • Middle Aged
  • Memory
  • Male
  • Humans
  • Haloperidol
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Levin, E. D., Wilson, W., Rose, J. E., & McEvoy, J. (1996). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15(5), 429–436. https://doi.org/10.1016/S0893-133X(96)00018-8
Levin, E. D., W. Wilson, J. E. Rose, and J. McEvoy. “Nicotine-haloperidol interactions and cognitive performance in schizophrenics.Neuropsychopharmacology 15, no. 5 (November 1996): 429–36. https://doi.org/10.1016/S0893-133X(96)00018-8.
Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996 Nov;15(5):429–36.
Levin, E. D., et al. “Nicotine-haloperidol interactions and cognitive performance in schizophrenics.Neuropsychopharmacology, vol. 15, no. 5, Nov. 1996, pp. 429–36. Pubmed, doi:10.1016/S0893-133X(96)00018-8.
Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996 Nov;15(5):429–436.
Journal cover image

Published In

Neuropsychopharmacology

DOI

ISSN

0893-133X

Publication Date

November 1996

Volume

15

Issue

5

Start / End Page

429 / 436

Location

England

Related Subject Headings

  • Schizophrenia
  • Reaction Time
  • Psychiatry
  • Nicotinic Agonists
  • Nicotine
  • Middle Aged
  • Memory
  • Male
  • Humans
  • Haloperidol